This Week In HIV Research


This Week in HIV Research: The Early Treatment Bandwagon; New U.S. Surveillance Data; Hep C Treatment Cost Effectiveness; and More

June 26, 2015

This week, the United Kingdom took a big step toward universal HIV treatment, there was an influx of new data for one of the most visually engaging HIV surveillance tools in the U.S. and some important new context was gained for discussions ranging from the cost of hepatitis C treatment to the centrality of nutrition in HIV treatment success. We touch on these stories, as well as a few others that may have slipped under the HIV research radar.

To beat HIV, you have to follow the science!

Clinical/Research Guidelines

All With HIV Should Be on Treatment, Draft British Guidelines Say

Our colleagues on the other side of the pond have officially drunk the early HIV treatment Kool-Aid. An updated set of draft treatment guidelines newly posted by the British HIV Association (BHIVA) recommends that antiretroviral therapy be initiated in all people living with HIV -- but, importantly, also notes that such people should be "ready to commit to taking therapy." BHIVA is accepting comments on the updated guidelines now, and plans to publish a final version in early August.

HOPE Act Research Criteria for HIV-Positive Organ Transplantation Are Posted

The U.S. National Institutes of Health posted draft criteria for research that explores the safety of organ transplantation between HIV-positive individuals. The effort is associated with the HIV Organ Policy Equity (HOPE) Act, a U.S. law that revises previous legislation that had banned the transplantation of organs from HIV-positive people. The draft research criteria were published June 18; comments are being accepted until Aug. 17.


AIDSVu Releases Updated U.S. HIV Surveillance Data, Resources

In advance of the U.S.'s annual National HIV Testing Day on June 27, AIDSVu -- an interactive, visual representation of U.S. HIV surveillance data (sometimes down to the neighborhood level, within select cities) -- launched an updated version of its website and released a bevy of new maps, infographics and highlighted information.

Hepatitis C

The Costs and Benefits of New Hepatitis C Treatment Interventions

Thanks to a team of U.S. researchers, we now have what may be our first in-depth examination of the cost-effectiveness of the newest generation of hepatitis C virus treatment regimens relative to older therapies (or no therapy at all). Also worth reading: a commentary on the findings by Michael Saag, M.D., the director of the Center for AIDS Research at the University of Alabama-Birmingham -- if for no other reason than how he manages to tie hepatitis C drug pricing and access to the iconic 1960s sitcom Get Smart.

In the Clinic

Food Insufficiency Associated With Lack of HIV Viral Suppression

There is an independent association between consistent food insufficiency and unsuppressed viral load among people with HIV, according to a longitudinal study of 2,118 HIV-positive people participating in food and nutrition programs in New York City. The findings provide a new example for how HIV treatment access is often not enough, in and of itself, to guarantee viral suppression.


No Link Found Between Oral PrEP Use and Depression

Although symptoms of depression were very common among iPrEx study participants, they were no more likely to occur among those who were randomized to receive an active oral pre-exposure prophylaxis (PrEP) regimen than those who were randomized to receive a placebo regimen, according to a study published in AIDS and Behavior. The iPrEx study, which enrolled men and transgender women who have sex with men, provided the first solid statistical evidence of PrEP's efficacy.


IL-21 May Play Key Role in Limiting Early HIV Infection

By triggering CD4 cells to pump out more of a small RNA molecule called microRNA-29, interleukin-21 (IL-21) limits HIV replication soon after infection, according to results of tissue and mouse studies conducted by U.S. researchers. The investigators believe their findings, which were published June 25 in Nature Communications, offer insight into the first steps of HIV infection and could inform strategies that limit the magnitude of early HIV infection.

Is there a development this week in HIV research that you think we missed? Send us a tip!

Myles Helfand is the editorial director of and

Follow Myles on Twitter: @MylesatTheBody.

Copyright © 2015 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.